Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state

Journal of Pharmaceutical Sciences

Volumn 97, Issue 4, 2008, Pages 1329-1349

  Bhugra, Chandan ^a,b   Pikal, Michael J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Amorphous state; Crystallization; Molecular mobility in glasses; Nucleation; Preparation of amorphous solids; Stability; Thermodynamics of crystallization

Indexed keywords

2 PROPANOL; ALCOHOL; CHROMIUM; DRUG ADDITIVE; EXCIPIENT; FELODIPINE; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; INDOMETACIN; KETOCONAZOLE; METAL OXIDE; METHANOL; MOLYBDENUM; ORGANIC SOLVENT; POLYMER; SALICIN; SILICATE;

CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; FOURIER TRANSFORMATION; HYDROGEN BOND; INFRARED SPECTROSCOPY; KINETICS; MOLECULAR DYNAMICS; PROTON NUCLEAR MAGNETIC RESONANCE; RAMAN SPECTROMETRY; REVIEW; SOLID; TEMPERATURE; THERMODYNAMICS; SOLUBILITY;

CRYSTALLIZATION; KINETICS; SOLUBILITY; THERMODYNAMICS;

EID: 43249092894     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21138     Document Type: Review

References (88)

1. Amidon GL, Lennernaes H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
2. Gupta P, Chawla G, Bansal AK. 2004. Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility. Mol Pharm 1:406-413.
3. Shamblin SL, Hancock BC, Pikal MJ. 2006. Coupling between chemical reactivity and structural relaxation in pharmaceutical glasses. Pharm Res 23:2254-2268.
4. Pikal MJ, Lukes AL, Lang JE. 1977. Thermal decomposition of amorphous b-lactam antibacterials. J Pharm Sci 66:1312-1316.
5. Guo Y, Byrn SR, Zografi G. 2000. Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. J Pharm Sci 89:128-143.
6. Aso Y, Yoshioka S, Kojima S. 2000. Relationship between the crystallization rates of amorphous nifedipine, phenobarbital, and flopropione, and their molecular mobility as measured by their enthalpy relaxation and 1H NMR relaxation times. J Pharm Sci 89:408-416.
7. Aso Y, Yoshioka S, Kojima S. 2001. Explanation of the crystallization rate of amorphous nifedipine and phenobarbital from their molecular mobility as measured by 13C nuclear magnetic resonance relaxation time and the relaxation time obtained from the heating rate dependence of the glass transition temperature. J Pharm Sci 90:798-806.
8. Aso Y, Yoshioka S, Kojima S. 2004. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions. J Pharm Sci 93:384-391.
9. Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. 2002. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci 91:1863-1872.
10. Surana R, Pyne A, Suryanarayanan R. 2004. Effect of preparation method on physical properties of amorphous trehalose. Pharm Res 21:1167-1176.
11. Shamblin SL, Zografi G. 1999. The effects of absorbed water on the properties of amorphous mixtures containing sucrose. Pharm Res 16:1119-1124.
12. Andronis V, Zografi G. 2000. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J Non-Crystalline Solids 271: 236-248.
13. Alie J, Menegotto J, Cardon P, Duplaa H, Caron A, Lacabanne C, Bauer M. 2004. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance. J Pharm Sci 93:218-233.
14. Gupta ManishK, Vanwert A, Bogner Robin H. 2003. Formation of physically stable amorphous drugs by milling with Neusilin. J Pharm Sci 92:536-551.
15. Gutzow I, Grigorova T, Todorova S. 2002. Kinetics of vitrification, glass relaxation and devitrification: A unified treatment. J Non-Crystalline Solids 304:4-18.
16. Minoru Yoshioka, Hancock BrunoC, Zografi G. 1994. Crystallization of Indomethacin from the amorphous state below and above its glass tranis-tion. J Pharm Sci 83:1700-1705.
17. Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P, Kinget R. 2001. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci 12:261-269.
18. Gupta P, Bansal AK. 2005. Molecular interactions in celecoxib-PVP- meglumine amorphous system. J Pharm Pharmacol 57:303-310.
19. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
20. Parks GS, Snyder LJ, Cattoir FR. 1934. Studies on glass. XI. Some thermodynamic relations of glassy and alpha-crystalline glucose. J Chem Phys 2:595-598.
21. Gupta P, Kakumanu VK, Bansal AK. 2004. Stability and solubility of Celecoxib-PVP amorphous dispersions: A molecular perspective. Pharm Res 21:1762-1769.
22. Mullin JW. 2001. Crystallization. 4th edition Burlington, MA: Elsevier Butterworth-Heinemann.
23. Gutzow I, Schmelzer J. 1995. The Vitreous State: Thermodynamics, Structure, Rheology, and Crystallization. Springer-Verlag Berlin and Heidelberg GmbH & Co. KG. Book, 470 pp.
24. James PF. 1985. Kinetics of crystal nucleation in silicate glasses. J Non-Crystalline Solids 73:517-540.
25. Naír Rodríguez-hornedo DM. 1999. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J Pharm Sci 88:651-660.
26. Shneidman VA. 1995. Theory of time-dependent nucleation and growth during a rapid quench. J Chem Phys 103:9772-9781.
27. Demo P, Kozisek Z. 1996. Transient nucleation. Thermochimica Acta 280-281:101-126.
28. Gutzow I, Dobreva A. 1996. Crystallization of glass forming melts. Ber Bunsenges Phys Chem 100:1415-1422.
29. Gutzow I, Schmelzer J, Dobreva A. 1997. Kinetics of transient nucleation in glass-forming liquids: A retrospective and recent results. J Non-Crystalline Solids 1-16.
30. Kashchiev D. 1969. Solution of the non-steady state problem in nucleation kinetics. Surf Sci 14:209-220.
31. Gutzow I, Avramov I, Kastner K. 1990. Glass formation and crystallization. J Non-Crystalline Solids 123:97-113.
32. Aso Y, Yoshioka S, Kojima S. 2001. Feasibility of using isothermal microcalorimetry to evaluate the physical stability of amorphous nifedipine and phe-nobarbital. Thermochimica Acta 380:199-204.
33. Avrami M. 1939. Kinetics of Phase Change. I General Theory. J Chem Phys 7:1103-1112.
34. Avrami M. 1940. Kinetics of phase change. II Transformation-time relations for random distribution of nuclei. J Chem Phys 8:212-224.
35. Shneidman VA, Uhlmann DR. 1998. Crystallization kinetics in a glass-forming melt with retarded viscosity. J Non-Crystalline Solids 223:48-52.
36. Yoshioka M, Hancock BC, Zografi G. 1995. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J Pharm Sci 84:983-986.
37. Vyazovkin S, Dranca I. 2005. Physical stability and relaxation of amorphous indomethacin. J Phys Chem B 109:18637-18644.
38. Marsac PJ, Konno H, Taylor LS. 2006. A comparison of the physical stability of amorphous felodipine and Nifedipine. Pharm Res 23:2306-2316.
39. Hikima T, Hanaya M, Oguni M. 1996. Beta molecular rearrangement process, but not an alpha-process, as governing the homogeneous crystal-nucleation rate in supercooled liquid. Bull Chem Soc Jpn 69:1863-1868.
40. Gupta P, Bansal AK. 2005. Devitrification of amorphous celecoxib. AAPS Pharm Sci Tech [electronic resource] 6:E223-E230.
41. Crowley Kieran J, Zografi G. 2002. Cryogenic grinding of indomethacin polymorphs and solvates: Assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci 91:492-507.
42. Bhugra C, Pikal MJ, Shmeis R. 2005. Crystallization and relaxation behavior of melt quenched Indo-methacin - Role of mechanical stress. Abstract, NERDG - 2005. CT: Rocky Hill.
43. Siniti M, Carre J, Letoffe JM, Bastide JP, Claudy P. 1993. The thermal behaviour of hexitols: Part 1. Vitrification and crystallization of iditol, mannitol, sorbitol and dulcitol. Thermochimica Acta 224:97-104.
44. Carpentier L, Desprez S, Descamps M. 2003. Crystallization and glass properties of pentitols. Xylitol, adonitol, arabitols. J Therm Anal Calorim 73:577-586.
45. Angell CA, Green JL. 2004. Thermodynamics and dynamics of glassforming systems. Biotechnol: Pharm Asp 2: (Lyophilization of Biopharmaceuticals): 367-122.
46. Ghebremeskel AN, Vemavarapu C, Lodaya M. 2006. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Stability testing of selected solid dispersions. Pharm Res 23:1928-1936.
47. Konno H, Taylor LS. 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 95:2692-2705.
48. Leinen KM, Labuza TP. 2006. Crystallization inhibition of an amorphous sucrose system using raffi-nose. J Zhejiang Univ Sci B 7:85-89.
49. Tang XC, Pikal MJ, Taylor LS. 2002. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm Res 19:477-483.
50. Tang XC, Pikal MJ, Taylor LS. 2002. The effect of temperature on hydrogen bonding in crystalline and amorphous phases in dihydropyrine calcium channel blockers. Pharm Res 19:484-490.
51. Gunawan L, Johari GP, Shanker RM. 2006. Structural relaxation of acetaminophen glass. Pharm Res 23:967-979.
52. Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. 2005. Role of molecular interaction in stability of celecoxib-PVP amorphous systems. Mol Pharm 2:384-391.
53. Taylor LS, Zografi G. 1997. Spectroscopic characterization of interactions between PVP and indo-methacin in amorphous molecular dispersions. Pharm Res 14:1691-1698.
54. Mura P, Maestrelli F, Cirri M, Furlanetto S, Pinzauti S. 2003. Differential scanning calorimetry as an analytical tool in the study of drug-cyclodextrin interactions. J Therm Anal Calorim 73:635-646.
55. Matsumoto T, Zografi G. 1999. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. Pharm Res 16:1722-1728.
56. Shamblin SL, Huang EY, Zografi G. 1996. The effects of co-lyophilized polymeric additives on the glass transition temperature and crystallization of amorphous sucrose. J Therm Anal 47: 1567-1579.
57. Karine Khougaz S-DC. 2000. Crystallization inhibition in solid dispersions of MK-0591 and poly (vinylpyrrolidone) polymers. J Pharm Sci 89: 1325-1334.
58. Weuts I, Kempen D, Decorte A, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2005. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64. Eur J Pharm Sci 25:313-320.
59. Andronis V, Yoshioka M, Zografi G. 1997. Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J Pharm Sci 86:346-351.
60. Miyazaki T, Yoshioka S, Aso Y, Kojima S. 2004. Ability of polyvinylpyrrolidone and polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. J Pharm Sci 93:2710-2717.
61. Pikal MJ. 2004. Mechanisms of protein stabilization during freeze-drying and storage: The relative importance of thermodynamic stabilization and glassy state relaxation dynamics. Drugs Pharm Sci 137: (Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products): 63-107.
62. Hancock BC, Zografi G. 1994. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res 11:471-477.
63. Saleki-Gerhardt A, Zografi G. 1994. Non-isothermal and isothermal crystallization of sucrose from the amorphous state. Pharm Res 11:1166-1173.
64. Johari GP, Ravi SK, Shanker M. 2007. Dielectric relaxation and crystallization of ultraviscous melt and glassy states of aspirin, ibuprofen, progesterone, and quinidine. J Pharm Sci 96:1159-1175.
65. Ngai KL, Magill JH, Plazek DJ. 2000. Flow, diffusion and crystallization of supercooled liquid: Revisited. J Chem Phys 112:1887-1892.
66. Richards WT. 1936. Remarks concerning the formation and crystallization of vitreous media. J Chem Phys 4:449-457.
67. Kauzmann W. 1948. The nature of the glassy state and the behavior of liquids at low temperatures. Chem Rev (Washington, DC, United States) 43: 219-256.
68. Hancock BC, Shamblin SL. 2001. Molecular mobility of amorphous pharmaceuticals determined using differential scanning calorimetry. Thermochimica Acta 380:95-107.
69. Hancock BC, Shamblin SL, Zografi G. 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res 12:799-806.
70. Hodge IM. 1994. Enthalpy relaxation and recovery in amorphous materials. J Non-Crystalline Solids 169:211-266.
71. Kawakami K, Pikal MJ. 2005. Calorimetric investigation of the structural relaxation of amorphous materials: Evaluating validity of the methodologies. J Pharm Sci 94:948-965.
72. Kawakami K. 2004. Investigation of the structural relaxation process of amorphous formulation by isothermal microcalorimetry. Netsu Sokutei 31: 74-79.
73. Liu J, Rigsbee DR, Stotz C, Pikal MJ. 2002. Dynamics of pharmaceutical amorphous solids: The study of enthalpy relaxation by isothermal microcalorimetry. J Pharm Sci 91:1853-1862.
74. Masuda K, Tabata S, Sakata Y, Hayase T, Yonemochi E, Terada K. 2005. Comparison of molecular mobility in the glassy state between amorphous indomethacin and salicin based on spin-lattice relaxation times. Pharm Res 22:797-805.
75. Apperley DC, Forster AH, Fournier R, Harris RK, Hodgkinson P, Lancaster RW, Rades T. 2005. Characterization of indomethacin and nifedipine using variable-temperature solid-state NMR. Magn Reson Chem 43:881-892.
76. Hikima T, Hanaya M, Oguni M. 1999. Microscopic observation of a peculiar crystallization in the glass transition region and [beta]-process as potentially controlling the growth rate in triphenylethylene. J Mol Struct 479:245-250.
77. Johari GP, Goldstein M. 1970. Viscous liquids and the glass transition. II. Secondary relaxations in glasses of rigid molecules. J Chem Phys 53:2372-2388.
78. Johari GP, Goldstein M. 1971. Viscous liquids and the glass transition. III. Secondary relaxations in aliphatic alcohols and other nonrigid molecules. J Chem Phys 55:4245-4252.
79. Correia NIT, Ramos JJM, Descamps M, Collins G. 2001. Molecular mobility and fragility in indomethacin: A thermally stimulated depolarization current study. Pharm Res 18:1767-1774.
80. Surana R, Pyne A, Suryanarayanan R. 2004. Effect of aging on the physical properties of amorphous trehalose. Pharm Res 21:867-874.
81. Legrand V, Descamps M, Alba-Simionesco C. 1997. Glass-forming meta-toluidine: A thermal and structural analysis of its crystalline polymorphism and devitrification. Thermochimica Acta 307:77-83.
82. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
83. Roberts CJ, Debenedetti PG. 2002. Engineering pharmaceutical stability with amorphous solids. AIChE J 48:1140-1144.
84. Craig DQM, Royall PG, Kett VL, Hopton ML. 1999. The relevance of the amorphous state to pharmaceutical dosage forms: Glassy drugs and freeze dried systems. Int J Pharm 179:179-207.
85. Patterson JE, James MB, Forster AH, Lancaster RW, Butler JM, Rades T. 2005. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. J Pharm Sci 94:1998-2012.
86. Tsukushi I, Yamamuro O, Suga H. 1994. Heat capacities and glass transitions of ground amorphous solid and liquid-quenched glass of tri-O-methyl-[ss]-cyclodextrin. J Non-Crystalline Solids 175:187-194.
87. Shamblin SL, Tang X, Chang L, Hancock BC, Pikal MJ. 1999. Characterization of the time scales of molecular motion in pharmaceutically important glasses. J Phys Chem B 103:4113-4121.
88. g. Pharm Res 23:2350-2355.